These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36252994)
21. Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study. Hu X; Cristino J; Gautam R; Mehta R; Amari D; Heo JH; Wang S; Wong ND Am J Prev Cardiol; 2023 Jun; 14():100476. PubMed ID: 36936405 [TBL] [Abstract][Full Text] [Related]
22. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. Nissen SE; Wolski K; Balog C; Swerdlow DI; Scrimgeour AC; Rambaran C; Wilson RJ; Boyce M; Ray KK; Cho L; Watts GF; Koren M; Turner T; Stroes ES; Melgaard C; Campion GV JAMA; 2022 May; 327(17):1679-1687. PubMed ID: 35368052 [TBL] [Abstract][Full Text] [Related]
23. Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels. Barth JA; Deckelbaum RJ; Starc TJ; Shea S; Mosca L; Berglund L J Lab Clin Med; 1999 Mar; 133(3):237-44. PubMed ID: 10072255 [TBL] [Abstract][Full Text] [Related]
24. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL. Li C; Chen Q; Zhang M; Liu Y; Chu Y; Meng F; Wang J; Tang J; Luo J; Niu X; Wei M BMC Cardiovasc Disord; 2021 Jan; 21(1):41. PubMed ID: 33468066 [TBL] [Abstract][Full Text] [Related]
25. Incremental Benefit of Lipid Lowering in a Large Chinese Population Aged 75 Years and Older With Established Atherosclerotic Cardiovascular Disease. Lin Z; Chen Y; Xiao Z; Xu W; Chen G; Huang C; Feng W; Xie Z; Liao W; Liao Y; Bin J; Feng L; Wang S Mayo Clin Proc; 2023 Sep; 98(9):1280-1296. PubMed ID: 37661139 [TBL] [Abstract][Full Text] [Related]
26. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Rikhi R; Hammoud A; Ashburn N; Snavely AC; Michos ED; Chevli P; Tsai MY; Herrington D; Shapiro MD Atherosclerosis; 2022 Dec; 363():102-108. PubMed ID: 36253168 [TBL] [Abstract][Full Text] [Related]
27. Lipoprotein(a) and mortality-a high risk relationship. Klingel R; Heibges A; Fassbender C Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):13-19. PubMed ID: 30838554 [TBL] [Abstract][Full Text] [Related]
28. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845 [TBL] [Abstract][Full Text] [Related]
29. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518 [TBL] [Abstract][Full Text] [Related]